

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 02877)**

### **ANNOUNCEMENT OF TURNOVER INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2010**

The Company is pleased to announce its financial information of turnover, which has not been reviewed by its auditors, for the three months ended 31 March 2010.

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce the preliminary financial information of turnover of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2010 based on its management accounts which have not been reviewed by the auditors.

Total turnover of the Group, which has not been reviewed by the auditors, for the three months ended 31 March 2010 increased by approximately 45.6% as compared with the same period of 2009 to approximately RMB435 million, and in particular:

- Turnover for the three months ended 31 March 2010 of injection products increased by approximately 72.5% as compared to the same period of 2009 to approximately RMB255 million;
- Turnover for the three months ended 31 March 2010 of soft capsule products increased by approximately 9.7% as compared to the same period of 2009 to approximately RMB95 million;
- Turnover for the three months ended 31 March 2010 of granule products increased by approximately 35.9% as compared to the same period of 2009 to approximately RMB78 million; and
- Products in other forms recorded turnover of approximately RMB7 million for the three months ended 31 March 2010.

In terms of product mix, injection products, soft capsule products and granule products accounted for approximately 58.6%, 21.9% and 17.9% of the total turnover respectively, all of which have not been reviewed by the auditors, for the three months ended 31 March 2010.

**Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.**

By order of the Board  
**China Shineway Pharmaceutical Group Limited**  
**Li Zhenjiang**  
*Chairman*

Hong Kong, 29 April 2010

*As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Wang Zhihua, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Hung Randy King Kuen and the independent non-executive Directors are Mr. Ren Dequan, Ms. Cheng Li and Mr. Sun Liutai.*